ADC Therapeutics has raised $550M-plus in its quest for their first BLA — and here’s why that’s important
The money train continues to chug in biopharma.
ADC Therapeutics has added one last batch of cash to its E round — a 2-year fundraising affair that is now being closed at $303 million. The money will fund a drive to their first planned BLA for their lead antibody-drug conjugate next year, with one pivotal study fully enrolled and another on the way.
ADC initially put together a $200 million round for the pivotal work, then added an extension that totals $103 million — slipping in $25 million from an unnamed “U.S.-based institutional investor, as well as additional investment from existing investors that participated in the previously announced $76 million Series E financing expansion.”
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 70,700+ biopharma pros reading Endpoints daily — and it's free.